Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal

J. Alarcão, R. Ascenção, J. Costa, M. Gouveia, M. Borges

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S104-S104
Number of pages1
JournalValue in Health
Volume21
DOIs
Publication statusPublished - Oct 2018
EventISPOR Europe 2018: New perspectives for improving 21st century health systems - Centre Convencions Internacional de Barcelona, Barcelona, Spain
Duration: 10 Nov 201814 Nov 2018

Keywords

  • Heart failure
  • Cost-effectiveness
  • Angiotensin-converting enzyme inhibitors
  • Angiotensin receptor neprilysin inhibitor
  • Sacubitril/valsartan

Cite this